Year: 2014
Type: review
Abstract: The known genetic cause of Huntington's disease (HD) has fueled considerable progress in understanding its pathobiology and the development of therapeutic approaches aimed at correcting specific changes linked to the causative mutation. Among the most promising is reducing expression of mutant huntingtin protein (mHTT) with RNA interference or antisense oligonucleotides; human trials are now being planned. Zinc-finger transcriptional repression is another innovative method to reduce mHTT expression. Modulation of mHTT phosphorylation, chaperone upregulation, and autophagy enhancement represent attempts to alter cellular homeostasis to favor removal of mHTT. Inhibition of histone deacetylases (HDACs) remains of interest; recent work affirms HDAC4 as a target but questions the assumed centrality of its catalytic activity in HD. Phosphodiesterase inhibition, aimed at restoring synaptic function, has progressed rapidly to human trials. Deranged cellular signaling provides several tractable targets, but specificity and complexity are challenges. Restoring neurotrophic support in HD remains a key potential therapeutic approach. with several approaches being pursued, including brain-derived neurotrophic factor (BDNF) mimesis through tyrosine receptor kinase B (TrkB) agonism and monoclonal antibodies. An increasing understanding of the role of glial cells in HD has led to several new therapeutic avenues, including kynurenine monooxygenase inhibition, immunomodulation by laquinimod, CB2 agonism, and others. The complex metabolic derangements in HD remain under study, but no clear therapeutic strategy has yet emerged. We conclude that many exciting therapeutics are progressing through the development pipeline, and combining a better understanding of HD biology in human patients, with concerted medicinal chemistry efforts, will be crucial for bringing about an era of effective therapies.
Source: Movement Disorders
DOI: 10.1002/mds.26007
Authors: Edward J. Wild, Sarah J. Tabrizi
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Keywords: Huntington's disease, mutant huntingtin, RNA interference, antisense oligonucleotides, autophagy, histone deacetylase inhibition, HDAC4, phosphodiesterase inhibition, synaptic function, neurotrophic support, brain-derived neurotrophic factor, monoclonal antibodies, glial cells, laquinimod, immunomodulation, metabolic disorders, therapeutic target, drug development pipeline
Open Access status: hybrid
Estimated APC paid: $2,067
Funders: CHDI Foundation, Teva Pharmaceutical Industries, Wellcome Trust, European Huntington's Disease Network, National Institute for Health and Care Research, Academy of Medical Sciences, Rosetrees Trust, University College London Hospitals NHS Foundation Trust, Medical Research Council, Biotechnology and Biological Sciences Research Council
OpenAlex ID: W2127930801
